Injective leadership forecasts accelerated timeline for US cryptocurrency ETF approvals
The CEO of Injective anticipates that exchange-traded funds based on the INJ token will receive regulatory approval and begin trading in the United States before 2027. Two separate ETF products—one from 21Shares and another from Canary focused on staked INJ—are currently pending approval from regulators. The executive's optimistic outlook suggests growing confidence in the regulatory pathway for cryptocurrency-based investment vehicles.
Injective's leadership has publicly stated expectations that regulatory bodies will greenlight exchange-traded fund products tied to the INJ token within the coming years. The approval timeline reflects the executive's assessment of momentum in the broader regulatory environment surrounding digital asset investment products. Two distinct proposals are currently under review—21Shares and Canary each submitted separate applications, with Canary's variant specifically structured around staked versions of the token, suggesting product differentiation in the pending pipeline.
If approved, these ETF products could broaden retail investor access to Injective's token through traditional brokerage accounts, potentially increasing demand and market participation. Regulatory green-lighting of such products may signal acceptance of cryptocurrency-based investment vehicles by US financial authorities, which could encourage additional similar applications across other digital assets. Conversely, approvals could intensify scrutiny around cryptocurrency market transparency and investor protection mechanisms, affecting how the broader industry structures future offerings.